Efficacy of Vonoprazan based therapy (Vonoprazan, Amoxycillin, Levofloxacin) versus Omeprazole based standard therapy for Helicobacter Pylori: A Multicenter Randomized Controlled Trial

Status

Unknown

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20221226002

Enrollment

158

Registered

2022-12-26

Start date

2022-11-23

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection Helicobacter pylori infection Eradication rate

Interventions

10 days of Vonoprazan based therapy for Helicobacter Pylori eradication Vonoprazan based therapy - Vonoprazan 20 mg po BID PC - Amoxycillin 1000 mg po BID PC - Levofloxacin 500 mg PO BID PC

Experimental Drug,Experimental Drug

Vonoprazan based therapy,Omeprazole based standard therapy

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients older than 20 year olds with H.pylori infection

Exclusion criteria

Exclusion criteria: History of H.pylori eradication Drug allergy to amoxycillin, clarithromycin, levofloxacin, omeprazole or vonoprazan Pregnancy or lactation HIV infection patient Active UGIB Hemodynamic unstability History of gastric cancer or surgery Chronic lung disease Active Tuberculosis infection

Design outcomes

Primary

Measure	Time frame
Eradication rate 4 weeks after end of treatment After treatment, successful H pylori eradication is recorded if negative Urea breath test	—

Secondary

Measure	Time frame
Adverse effects of treatment 2 weeks after end of treatment questionnaire interview	—

Countries

Thailand

Contacts

Public ContactSuttigiat Sangsuwan

Phramongkutklao hospital

suttigiat.s@gmail.com0862412196

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026